Skip to Main Content

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy

Conditions

Breast - Female | Breast - Male

Phase III

What is the purpose of this trial?

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

  • Trial with
    National Cancer Institute (NCI)
  • Start Date
    06/05/2017
  • End Date
    05/30/2026
Trial Image

For more information about this study, contact:

Courtney Barganier

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/19/2020
  • Study HIC
    #2000020555